» Articles » PMID: 31388758

[High Myopia in Vitrectomized Eyes : Contraindication for Minimally Invasive Glaucoma Surgery Implant?]

Overview
Journal Ophthalmologe
Specialty Ophthalmology
Date 2019 Aug 8
PMID 31388758
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Minimally invasive glaucoma surgery (MIGS) implants, such as XEN® gel stent are additional procedures in glaucoma treatment, which were designed to reduce the postoperative risk of severe hypotony and further complications. Until now the contraindications for every implant have not yet been identified. This case report describes the disastrous follow-up after implantation of a XEN® gel stent in the only high myopic eye of a patient. Despite elaborate subsequent interventions massive choroidal hemorrhage occurred with loss of the remaining visual field and total loss of visual acuity. The ocular pressure could be stabilized only after explantation of the XEN® gel stent. Patients with high myopia and the associated thin sclera, vitrectomized eyes and previous treatment with mitomycin C should be selected very carefully for XEN® gel stent. If these criteria are present the XEN® gel stent should be avoided whenever possible.

Citing Articles

Addressing Glaucoma in Myopic Eyes: Diagnostic and Surgical Challenges.

Vinod K, Salim S Bioengineering (Basel). 2023; 10(11).

PMID: 38002384 PMC: 10669452. DOI: 10.3390/bioengineering10111260.


Effectiveness and Safety of Xen Gel Stent in Glaucoma Surgery: A Systematic Review of the Literature.

Traverso C, Carassa R, Fea A, Figus M, Astarita C, Piergentili B J Clin Med. 2023; 12(16).

PMID: 37629380 PMC: 10455777. DOI: 10.3390/jcm12165339.


Ab-externo canaloplasty with and without suture in highly myopic eyes.

Urcola J, Illarramendi I, Lauzirika G Int Ophthalmol. 2023; 43(10):3695-3705.

PMID: 37415019 DOI: 10.1007/s10792-023-02779-y.


Efficacy and safety of XEN 45 gel stent alone or in combination with phacoemulsification in advanced open angle glaucoma patients: 1-year retrospective study.

Laborda-Guirao T, Cubero-Parra J, Hidalgo-Torres A Int J Ophthalmol. 2020; 13(8):1250-1256.

PMID: 32821679 PMC: 7387914. DOI: 10.18240/ijo.2020.08.11.